{"schema_version":"secwatch.filing_event.v1","accession":"0000805928-24-000025","form_type":"8-K","ticker":"AXGN","cik":"0000805928","company_name":"Axogen, Inc.","filed_at":"2024-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.967268+00:00","generated_at":"2026-06-05T04:25:58.220262+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Axogen reports Q4 2023 revenue $42.9M (+18.7% YoY); 2024 revenue guidance $177-181M","bullets":["Q4 net loss $3.9M ($0.09/share) vs $5.4M loss in Q4 2022; adjusted EBITDA turned positive at $0.6M.","Full-year 2023 revenue $159.0M (+14.7% YoY); net loss $21.7M vs $28.9M in 2022.","Gross margin declined: Q4 78.7% vs 83.0%; FY 80.4% vs 82.6%. Guidance expects 76-79% for 2024.","FDA pre-BLA agreement for Avance nerve graft; rolling submission in Q3 2024, potential approval mid-2025.","Avive+ Soft Tissue Matrix launch planned in Q2 2024; core accounts grew 13.3% to 376."],"urls":{"canonical":"https://secwatch.observer/filing/0000805928-24-000025","json":"https://secwatch.observer/filing/0000805928-24-000025.json","markdown":"https://secwatch.observer/filing/0000805928-24-000025.md","text":"https://secwatch.observer/filing/0000805928-24-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000025/0000805928-24-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000025/axgn-20240305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T04:25:58.220262+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f6790535043cafe20ccca4748f65183a75ee4e4","claim":"Axogen, Inc. updated its the fourth quarter and full-year ended December 31, 2023 guidance (raised).","evidence_excerpt":"On March 5, 2024 Axogen, Inc. (the “Company”) issued a press release announcing its fourth quarter and full year 2023 financial results.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000025/0000805928-24-000025-index.htm","confidence":0.5,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full-year ended December 31, 2023"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}